MEDICAL RECORD 
CONTINUATION SHEET for either: 
NIH 2514-1, Consent to Participate In A Clinical Research Study - 
NIH 2514-2, Minor Patient's Assent to Participate In A Clinical Research Study 
^TUOY NUMBER: CONTINUATION: page _Lof 11 . pages. 
shown to respond to them. The average amount of time myeloma 
patients live after diagnosis has been increased by these 
treatments. However, none of these standard treatments have 
been shown to make the myeloma disappear forever. 
Higher doses of chemotherapy and radiation are able to 
destroy a greater number of myeloma cells, but these high 
doses also destroy normal bone marrow cells and can not be 
tolerated without receiving a bone marrow transplant as a 
"rescue". A bone marrow transplant from another person (an 
"allogeneic" bone marrow transplant) is one method to allow 
very high doses of chemotherapy and radiation to be given. 
This type of transplant has been done in a number of patients 
with multiple myeloma, and some of them may have been cured by 
this procedure. But allogeneic bone marrow transplants are 
very risky, especially in patients over the age of 40, and not 
every patient has a suitable bone marrow donor available. 
Either because of your age, other risk factors, or the lack of 
a suitable donor, you and’ your doctors have decided not to 
pursue an allogeneic transplant. 
In this research study we instead propose to harvest and 
then freeze your own bone marrow cells after you have received 
standard chemotherapy to reduce the number of tumor cells in 
your marrow as far as* possible. We also propose to collect 
and then freeze cells that circulate in your blood called 
peripheral blood stem cells (PBSC) that can help replenish 
your bone marrow after high-dose chemotherapy and radiation. 
After cells have been harvested both from your bone marrow and 
from your blood, you will receive very high-dose chemotherapy 
with a drug called melphalan, and radiation treatments to you 
entire body. You will then receive back an infusion of your 
own bone marrow and blood cells ("autologous" bone marrow 
transplant) . These cells should then migrate to the bone 
marrow cavity and form a new bone marrow that can produce all 
the necessary types of blood cells. 
Autologous transplants of bone marrow or peripheral blood 
or both have been used in over one hundred other patients with 
multiple myeloma and have reduced the amount of tumor present 
in most of these patients. Some patients have absolutely no 
evidence of any remaining tumor after this type of treatment, 
but we do not yet know if they will have been cured of their 
tumor. Some patients have had relapses of their tumor several 
months or years after this type of treatment. Tumor cells 
ATIENT IDENTIFICATION 
CONTINUATION SHEET for either: 
NIH-251 4-1 (10-64} 
Recombinant DNA Research, Volume 16 
[71] 
